Vimarsana
Biggest News Aggregation in the World

Page 37 - Disease Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Disease Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Disease Study Today - Breaking & Trending Today

iron deficiency: Blood is life: 1 in 4 people globally suffer from anaemia - Vimarsana News

iron deficiency: Blood is life: 1 in 4 people globally suffer from anaemia

People become anemic when their blood lacks enough healthy red blood cells to carry oxygen throughout the body.

Pharmazz Inc. and Sun Pharma enter into licensing agreement - Vimarsana News

Pharmazz Inc. and Sun Pharma enter into licensing agreement

Sovateltide is a first of its kind drug to treat acute cerebral ischemic stroke that can be administered up to 24 hours after the onset of symptomsIndia is...

Progressive Charlestown - Vimarsana News

Progressive Charlestown

A fresh, sharp look at news, life and politics in Charlestown, Rhode Island

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets - Vimarsana News

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

/PRNewswire/ -- Menarini Asia-Pacific has entered into a long-term exclusive licensing partnership with Astellas Pharma Inc. (Astellas) for the development,...

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf(R) in Taiwan and select South-East Asian markets - Vimarsana News

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf(R) in Taiwan and select South-East Asian markets

Menarini Asia-Pacific has entered into a long-term exclusive licensing partnership with Astellas Pharma Inc. (Astellas) for the development, manufacturing and commercialization of the orally administered Janus kinase (JAK) inhibitor Smyraf(R) 50 mg